Cambridge Vasculitis Group. My leaving day. See you soon 🙂

KDIGO is pleased to announce the publication of the 2024 Clinical Practice Guideline for the Management of Lupus Nephritis, published today in the January 2024 issue of Supplement to Kidney International, with an Executive Summary published in the main pages of the journal. Read

Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage 🔓doi.org/10.1093/ndt/gf… Avacopan is associated with favourable outcomes in patients with AAV requiring respiratory support with a favourable safety profile. All patients survived & sustained remission.

🔥What is Avacopan 🙇‍♀️ 💊Oral C5a receptor antagonist 👩‍⚖️Advocate trial-Avacopan was non inferior to steroid in AAV in remission induction along with CYC/RITUX 👍Favourable outcomes even in pts of AAV with DAH NDT doi.org/10.1093/ndt/gf…

Much has changed in CKD care

Aglaia Chalkia presenting interesting data for ILD in ANCA-associated vasculitis from a European multicenter cohort Cambridge University ImmunRheumGr Vasculitis Workshop Barcelona #VasculitisBCN2024

Final criterias selected for defining #ANCA vasculitis responses: the BVAS (and its somehow difficulty to assess + lack of granularity for some acute organ damage - 👋🏻 the nephrologist in the room -) is still a major part of response assessment. Dr. S. Monti #vasculitisBCN2024

The June issue is online! 📖academic.oup.com/ndt/issue/39/6 Editor's choice: ANCA-associated vasculitis—treatment standard 🔓doi.org/10.1093/ndt/gf…

Many congrats to Alexandros Panagiotopoulos for providing an excellent presentation of their work on #lupus #nephritis drug discontinuation and flares Maria Tektonidou MJR #EULAR2024 #RheumTwitter

Back on inpatient service next week! American Society of Pediatric Nephrology #pediatrics #nephrology

Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage 🔓doi.org/10.1093/ndt/gf…